Employees: 86
Size Orchestra BioMed (OBIO) is a United States Health Care company (Medical Specialties) with a market value of $587M, the 2561st largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.46 on 18 Nov 2026.
Performance Over six months the shares gained 87.4%, against -12.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 1,007.4% over the last twelve months (peer median +6.5%); the operating margin is -195.4% (peer median 7.5%).
Valuation It trades at 18.3× enterprise value to sales against a peer median of 5.4× (2nd most expensive of 20).
Backlog Backlog (remaining performance obligations) was $11.0M at 31 Dec 2025, up 150% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Short interest Short interest is 4.5% of the free float (30 Oct 2026).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $31.2M | $33.5M | $2.64M | $2.76M | $3.53M |
| Revenue growth | — | +1,169% | -4% | -22% | — |
| Gross profit | $30.8M | $33.1M | $2.28M | $2.43M | $3.21M |
| EBITDA | -$60.6M | -$51.5M | -$64.0M | -$51.2M | -$32.4M |
| Net income | -$57.0M | -$52.7M | -$61.0M | -$49.1M | -$33.6M |
| Free cash flow | -$64.2M | -$49.5M | -$50.8M | -$46.2M | -$29.9M |
| Capital expenditure | $869,000 | $489,000 | $289,000 | $78,000 | $591,000 |
| Total debt | $73.5M | $32.4M | $16.5M | $1.69M | $11.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OBIO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +28.2% | -1.9% | 2nd highest of 19 |
| 6-month return | +87.4% | -12.6% | 2nd highest of 19 |
| Distance from 52-week high | -4.7% | -34.3% | 2nd highest of 20 |
| Revenue growth (TTM) | +1,007.4% | +6.5% | highest of 20 |
| Operating margin | -195.4% | 7.5% | lowest of 20 |
| EV / Sales | 18.3× | 5.4× | 2nd most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | 18.3× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 5.4× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 3.7× | 0.4% | +27.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 1.5× | 8.4% | +12.0% |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | 14.3× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | 6.4× | n/a | n/a |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 7.1× | -1.2% | +14.5% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 3.8× | 35.3% | +6.7% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 3.3× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | 6.7× | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 6.3× | 35.9% | +35.2% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 1.6× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | 5.9× | n/a | n/a |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 2.1× | -8.5% | +2.2% |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | 8.3× | -2.6% | +18.8% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | 5.5× | 15.0% | -19.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 2.1× | -11.5% | +6.7% |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | 26.5× | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | 0.8× | n/a | n/a |
Orchestra BioMed reported $11.0M of remaining performance obligations at 31 Dec 2025, up 150% from a year earlier. That is 0.3 years of trailing revenue already under contract.